AstraZeneca has announced the results from the EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial that showed cardiovascular safety with Bydureon (exenatide extended-release) in patients with type 2 diabetes at a wide range of CV risk.

The drug was found not to increase the incidence of major adverse cardiovascular events (MACE), a composite endpoint of CV death, non-fatal heart attack or non-fatal stroke, compared to placebo. There were also fewer CV events observed in the exenatide arm of the trial.

Recommended

Pharmacists could inject contraceptives

Community pharmacists could inject subcutaneous contraceptives but have concerns, research finds

Pharmacists need to improve their examination skills

Reluctance to examine patients limits pharmacists’ clinical reasoning skills

Popular

PHE updates guidance on managing common infections

PHE has updated its advice on ’Managing common infections: guidance for primary care’

NHS negligence bill quadruples in a decade

The Government must take steps to rein in the increasing cost of clinical negligence claims as numbers rocket, NAO warns

PDA and NPA demand patient safety pledge

The PDA and NPA have appealed to the Department of Health’s Rebalancing Board to adopt a patient safety ’pledge’